Study of Elobixibat (A3309) in Patients With Chronic Idiopathic Constipation

Responder Analyses for Complete Spontaneous Bowel Movements (CSBMs)

A CSBM responder is defined as per FDA draft guidance for IBS-C: An increase of one or more of CSBMs per week over baseline for at least 4 out of the 8 weeks of treatment

Time frame: Baseline, weekly and up to 8 weeks

Time to First Bowel Movement

Time frame: First week

Stool Consistency Change From Baseline

Bristol Stool Form Scale. Min value:1. Max value: 7. Higher value indicates more liquid shape than normal, lower indicates constipated state.

Time frame: Baseline, weekly and up to 8 weeks

LDL/HDL Ratio

Ratio of plasma LDL cholesterol and HDL cholesterol Difference from baseline, placebo-adjusted

Time frame: Baseline and 8 weeks of treatment

Straining Change From Baseline

Daily assessment of straining. Min value: 1. Max value: 5. Higher value indicates more straining.

Time frame: Baseline and during 8 weeks of treatment